| |
Among the most promising immunotherapy approaches are immune checkpoint blockade, adoptive cell therapies, therapeutic vaccines, oncolytic viruses, and mono, bi and trispecific antibodies. Download our white paper to explore advances in cancer immunotherapy and learn how Premier Research can maximize the potential of your program throughout the development lifecycle. +114x60.png)
|
|
Today’s Big NewsMay 23, 2024 |
| By Annalee Armstrong Cytokinetics has now all but assured that a buyout is nowhere in the near future with a $575 million Royalty Pharma funding deal that drew the ire of investors. |
|
|
|
By Annalee Armstrong Takeda has taken a trip all the way to Shanghai to find just the right kind of glue to stick together a $1.2 billion biobucks deal for new candidates in oncology, neuroscience and inflammation. |
By James Waldron Tango Therapeutics has discarded one of its cancer drugs on the dancefloor after the USP1 inhibitor was linked to reports of liver toxicity in a phase 1 trial. |
By Helen Floersh Palisade Bio’s PDE4 inhibitor to treat the inflammatory bowel disease ulcerative colitis appears to be effective in mice and doesn't cause toxicity in dogs, study findings presented at the annual Digestive Disease Week conference. |
|
One major hurdle in therapeutic development is the risk for unwanted immunogenicity, which can lead to decreased efficacy and safety. Gain insight into available tools and de-risk your pipeline - Join your colleagues to discuss on May 22 
|
|
By James Waldron Days after AstraZeneca set out how new oncology drugs would help fuel its “bold” ambition to almost double its revenue by the end of the decade, the Big Pharma has further swelled this pipeline via a deal with Harbour BioMed subsidiary Nona Biosciences. |
By Helen Floersh Clinical trial sites for cancer are proliferating, but a lack of investigators with experience in trial recruitment is weighing on their performance, according to a report released May 23 by trial analytics company Phesi. |
By Eric Sagonowsky Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. Now, the company has unveiled another savings drive that will run longer. |
By Helen Floersh Roche and the government of Abu Dhabi have set up a new public-private partnership to study spinal muscular atrophy and Duchenne muscular dystrophy in the Middle East. |
By Conor Hale According to a report from the San Diego Union-Tribune, the company will shutter operations at the end of this week, while laying off its remaining staff and leadership. |
By Paige Minemyer A key senator is calling on the Centers for Medicare & Medicaid Services to crack down on brokers who submit fraudulent enrollments for Affordable Care Act plans. |
By Kevin Dunleavy MilliporeSigma, the Massachusetts-based contract manufacturing arm of Merck KGaA, is increasing its presence in the gene therapy manufacturing field as it has signed an agreement to acquire Mirus Bio for $600 million. The Wisconsin-based company develops and commercializes transfection reagents, which allow genetic material to be incorporated into cells. |
Fierce podcasts Don’t miss an episode |
| This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
Whitepaper This detailed case study shows how Fresenius Medical Care achieved 25 times faster insights to help kidney disease patients, launching the world’s largest global database of dialysis care with fully anonymized patient data. Sponsored by: Privacy Analytics, an IQVIA company |
Whitepaper Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
Whitepaper Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
